• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Congress blocks pay drop, but 21% cut looms in 2010


Congress was able to block a pay cut for physicians who serve Medicare patients. Even though the American Society of Cataract and Refractive Surgery (ASCRS) and the American Academy of Ophthalmology (AAO) are pleased for the delay in the pay cut they maintain that the hard work is just beginning.

Washington, DC-Although physician advocacy groups are pleased that Congress was able to block a pay cut for physicians who serve Medicare patients, the American Society of Cataract and Refractive Surgery (ASCRS) and the American Academy of Ophthalmology (AAO) maintain that the hard work is just beginning.

Both groups say physicians and Medicare experts-not staffers and lobbyists-must decide how to reform the world's largest health-care system so that physicians are paid equitably. Such reform must be permanent, long-term, and appealing to a bipartisan, bicameral Congress, they said.

"Hard choices have to be made," said Nancey K. McCann, ASCRS director of government relations. "We can't continue to go down this path."

Congress staved off a 10.6% pay cut for Medicare physicians when it voted July 15 to override President Bush's veto earlier that day of the Medicare Improvements for Patients and Providers Act of 2008 (H.R. 6331) (See Ophthalmology Times, July 15, 2008, Pages 1 and 10). The bill provides a 1.1% increase in the physician payment rate through 2009. Because of a complex funding formula intended to control Medicare spending, however, physicians now face a 21% reduction in pay beginning Jan. 1, 2010.

"We don't view this as a win," McCann said, because a 1.1% update does not keep pace with inflation. ASCRS did not endorse the measure but chose not to speak out against it, she said.

Cathy G. Cohen, AAO vice president for governmental affairs, said Sen. Max Baucus (D-MT), the Senate's finance committee chairman, told medical group lobbyists that the medical community must come up with a plan to present to Congress for how it would change the funding formula, or it will be up to Congress to decide.

"This is something that's going to affect every specialty in medicine, so we really think it needs to be the physician leadership, not staff, coming together to make these decisions," Cohen said. "It's a very exciting time. We've been invited to come to the table and propose a new way to pay physicians, but it's also at great risk."

Medical groups such as the ASCRS and AAO are looking toward the American Medical Association (AMA) to provide leadership in reaching some consensus on changing the payment formula. The AMA said substantial reform to the physician payment question is necessary.

"This congressional debate underscores the need for lawmakers to replace the flawed Medicare physician payment formula permanently so physicians can focus on the real work at hand: taking care of patients," the AMA said in a prepared statement. "Current Medicare payments to physicians are about what they were in 2001, while the cost of running a medical practice has increased substantially."

Read the full story in the August 1 issue of Ophthalmology Times.

Related Videos
 John Bladen, MBBS, BSc, MRCS, PGCert, PhD, FRCOphth, consultant ophthalmologist and oculoplastic surgeon, King's College Hospital NHS Foundation Trust, London, UK, speaks with Ophthalmology Times Europe's® Caroline Richards
rande, CFP, and John S. Grande, CFP, of Grande Financial Services, continue their discussion with Ophthalmology Times®' Sheryl Stevenson
What keeps you up at night?
S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon
Caesar Luo, MD, shares his key take-aways on diabetic retinopathy progression in anti-VEGF versus FA implant
© 2023 MJH Life Sciences

All rights reserved.